Shares of women’s health drug developer TherapeuticsMD Inc. soared in late trading Monday after the company said its trial of a hormonal treatment to reduce vaginal pain during intercourse was successful.
In a final-stage trial of 764 post-menopausal woman, all three dosage levels of TherapeuticsMD’s estradiol treatment helped reduce pain during intercourse for post-menopausal patients with vulvar and vaginal atrophy, when compared to a placebo, the company said in a statement. Estradiol is a reproductive hormone that helps with the growth and maintenance of reproductive tissues. It also plays a key role during puberty.
The shares climbed as much as 65 percent, and were up 45 percent to $9.44 at 4:52 p.m. in New York after the market closed.
The softgel capsule, called TX-004HR, is Boca Raton, Florida-based TherapeuticsMD’s most advanced experimental product. It’s inserted into the vagina without using an applicator.
About 32 million women in the U.S. suffer from symptoms of vulvar and vaginal atrophy, a thinning and drying of the tissue that can lead to painful symptoms, though few are getting treatment, according to the drugmaker.